EnglishFrenchGermanItalianSpanish

NeuMoDx MOLECULAR SYSTEMS

Making COVID-19 Testing Easier For Everyone

We hope you and your team are staying healthy during this unprecedented time. Like many teams around the world, NeuMoDx Molecular has shifted our focus to provide solutions for testing and combating the SARS-CoV-2 virus. #We’re All In This Together.

Feel free to reach out to our support teams if you need anything. We are here.

POWERFUL. SIMPLE.
DIAGNOSTICS.

Industry’s First True Continuous Random-Access Solution

NeuMoDx™ Molecular Systems provide the industry’s first true continuous random-access solution and is scalable to meet the needs of the modern clinical laboratory. The ability to load samples and testing consumables on the fly offers up to 8 hours of operator walkaway capability. Room temperature stable reagents and consumables dramatically reduce waste resulting in unmatched flexibility. Liquid handling and transport is achieved through proven robotic technologies. Our proprietary and unitized microfluidic cartridge features autonomous lanes allowing for simultaneous processing of sample types and varying assays. This unique integration of robotics with advanced microfluidics, reduces operation to three simple steps providing industry leading usability. These capabilities dramatically improve lab productivity and the ability to provide clinicians with critical information in a timely manner.

What we do

Molecular systems

NeuMoDx™ Molecular Systems are a family of scalable platforms that fully integrate the entire molecular diagnostic process from “sample to result.” NeuMoDx™ 288 and NeuMoDx™ 96 Molecular Systems are fully automated, continuous random-access analyzers that utilize our proprietary NeuDry™ reagent technology, which integrates magnetic particle affinity capture and real time polymerase chain reaction (PCR) chemistry in a multi-sample microfluidic cartridge.

 

WHAT THE EXPERTS ARE SAYING

The Difference Between NeuMoDx and the Competition

Watch the video
WHY CHOOSE OUR SOLUTION FOR YOUR LAB?

FULLY AUTOMATED. CONTINUOUS RANDOM-ACCESS

NeuMoDx machine

IMPORTANT ANNOUNCEMENT

We are excited to announce that QIAGEN has acquired all shares of NeuMoDx Molecular, Inc. The addition of NeuMoDx’s medium- and high-throughput molecular systems further expands QIAGEN’s portfolio of molecular diagnostics instruments, bolstering our leadership in automated molecular testing. We are proud to welcome NeuMoDx to our family of PCR solutions that make improvements in life possible.

To learn more, click here.